Drugs / SP-102
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03613662 | Jul 2018 → Mar 2019 | radiculopathy | Semnur Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07579351 | Aug 2026 → Jul 2028 expected | sciatica | Semnur Pharmaceuticals, Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03372161 | Dec 2017 → Aug 2021 | radiculopathy | Scilex Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SP-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03372161 ↗ |
| Route | Other | “delivered by transforaminal injection” PMID 38875121 ↗ Jun 2024 |